Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

192.98USD
4:00pm EDT
Change (% chg)

$-0.50 (-0.26%)
Prev Close
$193.48
Open
$195.51
Day's High
$196.25
Day's Low
$191.68
Volume
59,811
Avg. Vol
127,956
52-wk High
$202.42
52-wk Low
$36.52

Chart for

About

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290... (more)

Overall

Beta: --
Market Cap(Mil.): $10,363.72
Shares Outstanding(Mil.): 4.12
Dividend: --
Yield (%): --

Financials

  BGNE.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -3.14 -- --
ROI: -15.45 -7.38 12.74
ROE: -17.48 -10.11 14.64

BRIEF-Beigene Initiates Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer

* BEIGENE INITIATES PHASE 3 TRIAL OF PAMIPARIB AS MAINTENANCE THERAPY IN CHINESE PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 17 2018

BRIEF-Beigene Reports Q1 Net Loss per ADS $2.03

* REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MILLION, COMPARED TO NIL IN SAME PERIOD IN 2017

May 09 2018

BRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million

* BEIGENE LTD SAYS CEO JOHN V. OYLER'S 2017 TOTAL COMPENSATION WAS $10.3 MILLION – SEC FILING Source : https://bit.ly/2r6wtIy Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

Apr 16 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors

* BEIGENE APPOINTS J. SAMUEL SU TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-BeiGene Qtrly Net Loss Per ADS $2.19

* BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 28 2018

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage:

Feb 08 2018

BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China

* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZA® (AZACITIDINE FOR INJECTION) IN CHINA

Feb 05 2018

Earnings vs. Estimates